Cure My Disease

Don't miss your cure!

 Log in / Sign up

Tracking asthma care: why some patients stay uncontrolled

NCT ID NCT06422663

Knowledge-focused Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 04, 2026 · Last updated Sep 04, 2026

Summary

This study follows 500 people in China with moderate-to-severe asthma to see how doctors adjust their treatments over 24 weeks. Researchers focus on patients whose symptoms remain uncontrolled despite using standard inhaler therapy, and they track whether these patients are moved to stronger medications. The goal is to describe real-world treatment patterns and understand how many patients still struggle with asthma control. This is an observational study, so no new treatment is being tested.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
This study could reveal gaps in asthma care in China and help guide better treatment strategies for patients whose symptoms remain uncontrolled.
What could go wrong
Because this is an observational study, it cannot prove what works best. It only describes current practices, and results may not apply beyond the patients studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

500 people

The number who actually took part.

Started

Mar 2024

Finished

Mar 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Moderate-to-Severe Asthma Patients

Ages

12 to 130 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Physician-confirmed asthma diagnosis with documented evidence of variable expiratory airflow limitation (e.g., from bronchodilator reversibility testing or other tests) 2. Written informed consent 3. Moderate-to-severe asthma, which is defined as asthma patients with maintenance. treatment of GINA Step 3-5. 4. Age 12 years old and above Exclusion Criteria: 1. Previous diagnosis of chronic obstructive pulmonary disease (COPD) or other clinically relevant chronic respiratory disease other than asthma 2. Received an investigational therapy for asthma, allergy, atopic disease, or eosinophilic disease as part of a clinical trial during the 6 months prior to enrolment. (Once enrolled in the PRESENT Study, patients should not enrol in any investigational trials.) 3. Any significant disease or disorder which, in the opinion of the investigator, may either put the patient at risk because of participation in the study, or may influence the results of the study, or the patient's ability to participate in the study 4. Disease or condition other than asthma that requires treatment with systemic or oral steroids 5. Patients with poor inhaler skills and adherence

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Moderate-to-severe asthma are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

asthma chronic asthma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Moderate-to-severe asthma

Contacts and locations

Locations

  • Research Site

    Baoding, China

  • Research Site

    Beijing, China

  • Research Site

    Changsha, China

  • Research Site

    Chengdu, China

  • Research Site

    Chongqing, China

  • Research Site

    Dingzhou, China

  • Research Site

    Hangzhou, China

  • Research Site

    Harbin, China

  • Research Site

    Hefei, China

  • Research Site

    Hohhot, China

  • Research Site

    Jinan, China

  • Research Site

    Kunming, China

  • Research Site

    Liuzhou, China

  • Research Site

    Lu'an, China

  • Research Site

    Luzhou, China

  • Research Site

    Nanchang, China

  • Research Site

    Nanchong, China

  • Research Site

    Qingdao, China

  • Research Site

    Quanzhou, China

  • Research Site

    Shanghai, China

  • Research Site

    Shenzhen, China

  • Research Site

    Tianjin, China

  • Research Site

    Tiaobingshan, China

  • Research Site

    Wenzhou, China

  • Research Site

    Wuhan, China

  • Research Site

    Xi'an, China

  • Research Site

    Xiamen, China

  • Research Site

    Yongzhou, China

  • Research Site

    Zhangjiagang, China

  • Research Site

    Zhengzhou, China

  • Research Site

    Zigong, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.